MedTrace Logo

Can Two Dietary Interventions Maintain Weight Loss for 12 Months After GLP-1 Therapy in Adults With Overweight/Obesity?

NCT07711548 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 292

Last updated 2026-07-20

No results posted yet for this study

Summary

So far, treatment with semaglutide (Wegovy) for therapy of obesity demonstrates substantial effects. However, most patients do not desire life-long pharmaceutical therapy or discontinue this treatment regime. This is accompanied by rapid weight regain. Moreover, numerous patients are open to an intermittent therapy.

This trial aims to investigate whether two diet interventions can keep weight stable after weight loss with semaglutide in people with obesity or overweight.

Conditions

  • Obesity & Overweight
  • Weight Loss Maintenance

Interventions

BEHAVIORAL

NutriAct plus

Dietary pattern, vegetarian version of the NutriAct pattern

BEHAVIORAL

Rescue VLCD

Very low calorie diet as full meal replacement over 28 days in case of weight regain

Sponsors & Collaborators

  • University of Latvia

    collaborator OTHER

  • Institute for Clinical and Experimental Medicine

    collaborator OTHER_GOV

  • University of Vienna

    collaborator OTHER

  • ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK (ECRIN)

    collaborator UNKNOWN

  • Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke (DIfE)

    collaborator UNKNOWN

  • German Federal Ministry of Research, Technology, and Space (BMFTR)

    collaborator UNKNOWN

  • Austrian Science Fund (FWF)

    collaborator OTHER

  • Czech Health Research Agency

    collaborator OTHER

  • Latvian Council of Science

    collaborator UNKNOWN

  • Ministry of Health, Czech Republic

    collaborator OTHER_GOV

  • DLR Project Management Agency (DLR)

    collaborator UNKNOWN

  • Knut Mai

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2027-03-31
Primary Completion
2030-02-28
Completion
2030-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07711548 on ClinicalTrials.gov